Pfizer faces a lawsuit in which women allege the drugmaker failed to warn them about the risks of meningioma associated with ...
The FDA contacted J&J right after ASH to discuss using a special fast pass on a multiple myeloma regimen. Elsewhere, a new ...
Representatives of companies including AbbVie, Eli Lilly, Johnson & Johnson and Merck have voiced concerns about the FDA’s ...
Pfizer's coronavirus vaccine could face some headwinds in the near future. The company will enter a period of patent cliffs ...
Morgan Stanley (MS) has issued a less optimistic outlook on the performance of the shares of American pharmaceutical giant ...
Shares of BioNTech, the German vaccine innovator, came under significant pressure on a pivotal Tuesday. The sell-off, which also dragged down sector peers in ...
Pfizer Is Still Struggling to Replace Its COVID Revenue. Here's What We Could See From the Pharmaceutical Giant in 2026. Keep ...
Pfizer's stock has fallen by more than 50% from its 2021 highs and faces some headwinds, but remains worth a deep dive for ...
Pfizer bets on YaoPharma’s oral GLP-1 pill YP05002 after past failures, aiming to rejoin the booming $150B obesity-drug market.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback